PMID- 34421988
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 12
DP  - 2021
TI  - Association Between Human Leukocyte Antigen Class I and II Diversity and 
      Non-virus-associated Solid Tumors.
PG  - 675860
LID - 10.3389/fgene.2021.675860 [doi]
LID - 675860
AB  - Homozygosity at human leukocyte antigen (HLA) loci might lead to reduced 
      immunosurveillance and increased disease risk, including cancers caused by 
      infection or of hematopoietic origin. To investigate the association between HLA 
      zygosity and risk of non-virus-associated solid tumors, we leveraged genome-wide 
      association study (GWAS) data from over 28,000 individuals of European ancestry 
      who participated in studies of 12 cancer sites (bladder, brain, breast, colon, 
      endometrial, kidney, lung, ovary, pancreas, prostate, skin, and testis). 
      Information on HLA zygosity was obtained by imputation; individuals were 
      classified as homozygotes at a given locus when imputed to carry the same 
      four-digit allele at that locus. We observed no evidence for an association 
      between zygosity at six HLA loci and all cancers combined. Increase in number of 
      homozygous at HLA class I loci, class II loci, or class I and II loci was also 
      not associated with cancer overall (P (trend) = 0.28), with adjusted odds ratios 
      (ORs) for risk-per-locus of 1.00 [95% confidence intervals (CIs) = 0.97, 1.03], 
      1.02 (0.99, 1.04), and 1.01 (0.99, 1.02), respectively. This study does not 
      support a strong role for HLA zygosity on risk of non-virus-associated solid 
      tumors.
CI  - Copyright (c) 2021 Liu and Hildesheim.
FAU - Liu, Zhiwei
AU  - Liu Z
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD, United States.
FAU - Hildesheim, Allan
AU  - Hildesheim A
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
      Bethesda, MD, United States.
LA  - eng
GR  - U01 HG004438/HG/NHGRI NIH HHS/United States
GR  - U01 HG004446/HG/NHGRI NIH HHS/United States
GR  - N01 CN25514/CA/NCI NIH HHS/United States
GR  - HHSN261201000006C/CP/NCI NIH HHS/United States
GR  - N02 CP001037/CP/NCI NIH HHS/United States
GR  - N01 CN25524/CA/NCI NIH HHS/United States
GR  - N01 CN25513/CA/NCI NIH HHS/United States
GR  - N01 CN25518/CA/NCI NIH HHS/United States
GR  - N01 CN25516/CA/NCI NIH HHS/United States
GR  - N01 CN25476/CA/NCI NIH HHS/United States
GR  - N01 CN25404/CA/NCI NIH HHS/United States
GR  - N01 CN75022/CA/NCI NIH HHS/United States
GR  - HHSN268200782096C/HG/NHGRI NIH HHS/United States
GR  - N01 CN25512/CA/NCI NIH HHS/United States
GR  - N01 CN25511/CA/NCI NIH HHS/United States
GR  - N01RC37004/RC/CCR NIH HHS/United States
GR  - N01CO12400/CA/NCI NIH HHS/United States
GR  - N01 CN045165/CN/NCI NIH HHS/United States
GR  - N01 CN25522/CA/NCI NIH HHS/United States
GR  - N01 CN25515/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20210804
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC8371526
OTO - NOTNLM
OT  - Caucasian
OT  - association
OT  - human leukocyte antigen
OT  - solid tumor
OT  - zygosity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
PMCR- 2021/08/04
CRDT- 2021/08/23 06:27
PHST- 2021/03/05 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/08/23 06:27 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
PHST- 2021/08/04 00:00 [pmc-release]
AID - 10.3389/fgene.2021.675860 [doi]
PST - epublish
SO  - Front Genet. 2021 Aug 4;12:675860. doi: 10.3389/fgene.2021.675860. eCollection 
      2021.